FIG 4 .
Gly-MCA efficiently ameliorates obesity-related metabolic disorders by FXR inhibition. Relative abundance of the significantly changed metabolites in the liver obtained from vehicle-treated mice, Gly-MCA-treated mice, and Gly-MCA-treated mice administered GW4064 (A); Fxrfl/fl and FxrΔIE mice with and without Gly-MCA treatment (B); SCFAs (acetate, butyrate, and propionate) and oligosaccharides in the cecal contents from vehicle-treated mice, Gly-MCA-treated mice, and Gly-MCA-treated mice administered GW4064 (C). n = 5 mice per group. Data are means ± SD (n = 5 per group). *, P < 0.05; **, P < 0.01 (compared with vehicle treatment). #, P < 0.05; ##, P < 0.01 (compared with Gly-MCA treatment of HFD-fed mice). Data were analyzed via a one-way ANOVA with Tukey’s correction.